.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Novartis
Colorcon
Daiichi Sankyo
Medtronic
Mallinckrodt
Cantor Fitzgerald
Queensland Health
Julphar

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,855,190

« Back to Dashboard

Which drugs does patent 7,855,190 protect, and when does it expire?


Patent 7,855,190 protects LOSEASONIQUE and SEASONIQUE and is included in two NDAs. There have been zero Paragraph IV challenges on LoSeasonique and Seasonique

This patent has twenty-three patent family members in eleven countries.

Summary for Patent: 7,855,190

Title:Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Abstract:The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
Inventor(s): Bell; Robert G. (Palm Harbor, FL), Ben-Maimon; Carole S. (Merion, PA), Iskold; Beata (Livingston, NJ), Bronnenkant; Lance J. (Snyder, NY), Hait; Howard (Wilmington, DE), Reape; Kathleen Z. (Bryn Mawr, PA)
Assignee: Teva Women's Health, Inc. (Woodcliff Lake, NJ)
Application Number:10/892,404
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Branded PharmLOSEASONIQUEethinyl estradiol; levonorgestrelTABLET;ORAL022262-001Oct 24, 2008ABRXNoNo► Subscribe► SubscribePREVENTION OF PREGNANCY► Subscribe
Teva Branded PharmSEASONIQUEethinyl estradiol; levonorgestrelTABLET;ORAL021840-001May 25, 2006ABRXYesYes► Subscribe► SubscribePREVENTION OF PREGNANCY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,855,190

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,772,219Methods of hormonal treatment utilizing extended cycle contraceptive regimens► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,855,190

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)2005007112► Subscribe
World Intellectual Property Organization (WIPO)2004098517► Subscribe
Russian Federation2010118424► Subscribe
Russian Federation2006101214► Subscribe
Russian Federation2403046► Subscribe
New Zealand585546► Subscribe
New Zealand574964► Subscribe
New Zealand545130► Subscribe
Japan2011157389► Subscribe
Japan2007534622► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Novartis
Cerilliant
AstraZeneca
Julphar
Express Scripts
QuintilesIMS
Covington
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot